+1 858-523-8231
Login | Register
AA Blocks, Building Blocks, Catalysts, Inhibitors
Login | Register
Home Other Building Blocks 1187594-09-7
1187594-09-7,MFCD21608464
Catalog No.:AA003A32

1187594-09-7 | 2-(3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
99%
in stock  
$16.00   $11.00
- +
2mg
99%
in stock  
$24.00   $17.00
- +
5mg
99%
in stock  
$32.00   $22.00
- +
10mg
98%
in stock  
$43.00   $30.00
- +
25mg
≥95%
in stock  
$53.00   $37.00
- +
50mg
≥95%
in stock  
$85.00   $59.00
- +
250mg
98%
in stock  
$103.00   $73.00
- +
1g
99%
in stock  
$201.00   $141.00
- +
5g
98%
in stock  
$760.00   $532.00
- +
10g
98%
in stock  
$1,125.00   $788.00
- +
25g
98%
in stock  
$2,140.00   $1,498.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Literature
Technical Information
Catalog Number:
AA003A32
Chemical Name:
2-(3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile
CAS Number:
1187594-09-7
Molecular Formula:
C16H17N7O2S
Molecular Weight:
371.4169
MDL Number:
MFCD21608464
SMILES:
N#CCC1(CN(C1)S(=O)(=O)CC)n1ncc(c1)c1ncnc2c1cc[nH]2
Properties
Computed Properties
 
Complexity:
678  
Covalently-Bonded Unit Count:
1  
Heavy Atom Count:
26  
Hydrogen Bond Acceptor Count:
7  
Hydrogen Bond Donor Count:
1  
Rotatable Bond Count:
5  
XLogP3:
-0.5  

Literature

Title: Baricitinib in Patients with Refractory Rheumatoid Arthritis.

Journal: The New England journal of medicine 20160331

Title: Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib.

Journal: EBioMedicine 20150401

Title: Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.

Journal: Nature medicine 20140901

Title: Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases.

Journal: Journal of medicinal chemistry 20140626

Title: Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds.

Journal: Clinical and experimental immunology 20131201

Title: Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.

Journal: Journal of immunology (Baltimore, Md. : 1950) 20100501

Title: Fridman JS, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol. 2010 May 1;184(9):5298-307.

Title: Jabbari A, et al. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib. EBioMedicine. 2015 Feb 26;2(4):351-5.

Title: Khan IM, et al. Intermuscular and perimuscular fat expansion in obesity correlates with skeletal muscle T cell and macrophage infiltration resistance. Int J Obes (Lond). 2015 Nov;39(11):1607-18.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 1187594-09-7
Building Blocks
More >
Tags:1187594-09-7 Molecular Formula|1187594-09-7 MDL|1187594-09-7 SMILES|1187594-09-7 2-(3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile